In four large pedigrees with heterozygous familial hypercholesterolemia (FH) genetically linked to the low density lipoprotein receptor locus, we have observed a strong interaction between the presence of FH and a single apolipoprotein (apo) E2 allele, resulting in a markedly increased prevalence of type III dyslipoproteinemia (DLPIII). DLPIII was denned by chemical criteria. None of the patients with DLPIII had tuberous or palmar xanthomas characteristic of classically denned type HI hyperlipoproteinemia. After exclusion of four persons with apo E 2-2 phenotype, there were 89 FH patients and 110 non-FH subjects. Definite DLPIII (denned as a very low density lipoprotein [VLDL] cholesterol to plasma triglyceride ratio >0.30 with plasma triglycerides >150 mg/dl) was present in 26% of 43 FH patients with a single E2 allele compared with only 3.4% of 29 non-FH subjects with an E2 allele (p=0.003). To further characterize this interaction we performed a two-way analysis of covariance, after adjustment for age, sex, and body mass index, to test for any interaction between FH and the apo E loci. There was a statistically significant interaction between FH and the presence of a single E2 allele for the ratio of VLDL cholesterol to plasma triglycerides and for a newly derived estimate of /3-VLDL cholesterol concentration. Estimated /3-VLDL cholesterol level was strongly correlated with age in the subgroup with FH and an E2 allele but not in other subgroups. There was no difference in estimated /3-VLDL cholesterol between sexes. Correlation between estimated 0-VLDL cholesterol level and body mass index in persons older than 18 years was of only marginal significance and of similar magnitude in persons with or without an apo E2 allele. Present knowledge suggests that /3-VLDLs are highly atherogenic; if so, then a sizable subset of FH patients having at least one apo E2 allele and DLPIII may be at increased risk for premature coronary heart disease. {Arteriosclerosis and Thrombosis 1991;11:1137-1146) I n a single large pedigree with complex lipoprotein patterns, we observed type III dyslipoproteinemia (DLPIII) in most of the carriers of heterozygous familial hypercholesterolemia (FH) who also possessed a single apolipoprotein (apo) E2 allele. DLPIII was superimposed on the usual FH phenotype. 1 We have defined definite DLPIII as the Supported in part by a grant from the National Heart, Lung, and Blood Institute (HL-21088-12) 
I n a single large pedigree with complex lipoprotein patterns, we observed type III dyslipoproteinemia (DLPIII) in most of the carriers of heterozygous familial hypercholesterolemia (FH) who also possessed a single apolipoprotein (apo) E2 allele. DLPIII was superimposed on the usual FH phenotype. 1 We have defined definite DLPIII as the tion of DLPIII even in FH patients with a single apo E2 allele. This seemed reasonable because the LDL receptor, which is defective in FH, 2 is also involved in the processing of VLDL remnants that accumulate in the blood of DLPIII subjects. 3 While others have suggested that FH may promote phenotypic expression of DLPIII in patients with two E2 genes (apo E 2-2), 4 only one case has been previously reported of a DLPIII pattern associated with FH and a single E2 allele (apo E 4-2 phenotype). 5 The abnormal remnants of triglyceride-rich lipoproteins in DLPIII patients derive from both chylomicron and VLDL metabolism. 6 They accumulate in plasma as particles with VLDL density but with /3 electrophoretic mobility (as opposed to normal VLDL pre-/3 mobility), hence the designation /3-VLDL. /3-VLDLs are further characterized by a relatively high content of apo E and a much higher content of cholesterol esters compared with normal VLDL (mean cholesterol to triglyceride ratio of 0.59 in /3-VLDL compared with 0.21 in normal VLDL). 3 A chemical definition for definite DLPIII (VLDL cholesterol to plasma triglyceride ratio >0. 30 , with plasma triglycerides of 150-1,000 mg/dl) was found to predict with high specificity those persons who displayed a significant /3-VLDL band in the VLDL fraction (d< 1.006 g/ml) on paper or gel electrophoresis. 7 We have characterized several large FH pedigrees by the use of restriction fragment length polymorphisms (RFLPs) at the LDL receptor locus. 18 - 9 In each of these pedigrees a specific LDL receptor allele defined by RFLPs cosegregated with markedly elevated serum LDL cholesterol concentration. In this study we determined the frequency of DLPIII in these well-defined FH pedigrees and formally tested for an interaction between the presence of FH and possession of a single E2 allele. We observed a markedly increased risk for the development of DLPIII in FH patients having a single apo E2 allele.
Methods Family Ascertainment and Low Density Lipoprotein Receptor Linkage
Included in this study are four extensive pedigrees that were referred to the Cardiovascular Genetics Research Clinic, with striking elevations of total cholesterol affecting both children and adults and multiple cases of early coronary disease. The pattern of plasma total and/or LDL cholesterol in the families was consistent with a dominant mode of inheritance, as ascertained both by inspection (all pedigrees) and formal segregation analysis (in K26). 10 In one of the pedigrees (K653), tendinous xanthomas were relatively common. However, in the other pedigrees xanthomas were either rare or absent.
In all four pedigrees, elevated LDL cholesterol levels have been unambiguously linked to the LDL receptor by the use of various RFLPs. Details for three of these pedigrees have been reported (K625, 1 K26, 8 and K653 9 ). In the fourth kindred (K659), LDL receptor alleles were defined by Southern blots 1112 to reveal RFLPs. Products of restriction endonuclease Pvu II were probed with the pRHP17 genomic DNA clone of the LDL receptor. In addition, an RFLP with Pst I was revealed with the pRHP3A LDL receptor genomic DNA clone. 13 Linkage analysis demonstrated segregation of the high LDL cholesterol phenotype with the RFLP markers at the LDL receptor locus with an LOD (log of the odds) score of 3.52, signifying that the genetic model was 3,310 times more likely to explain the data than a chance or random association between the DNA marker and LDL cholesterol levels. 14 Other members of the four FH pedigrees were ascertained after the original DNA marker studies were performed. Such individuals were included for analyses if they were clearly linked by genealogical information to one of the original DNA-linked FH heterozygotes. There were no patients with plasma lipid levels suggestive of homozygous FH in any of the families. Furthermore, there was no known consanguinity in the pedigrees.
Diagnosis of FH and non-FH within these LDL receptor-marked pedigrees was made clinically by the presence of markedly elevated LDL cholesterol levels (>95th percentile and usually >99th percentile for age and sex), where there was a clear bimodal distinction between affected and unaffected family members. Where there may have been ambiguity (such as in the offspring of an FH heterozygote married to an unaffected spouse with elevated LDL cholesterol), results from DNA linkage studies were used to make the diagnosis. If an individual could not be clearly defined as FH or non-FH, he or she was excluded from further analysis.
Lipid Analyses and Apolipoprotein E Phenotyping
Blood samples were collected in the morning after 12-16 hours of fasting and prepared according to guidelines of the Lipid Research Clinics Program Manual of Laboratory Operations. 15 Lipids were measured by a microscale procedure developed in our laboratory. 16 Briefly, high density lipoprotein (HDL) was measured in the supernatant after precipitation of apo B-containing lipoproteins with dextran sulfate/MgCl 2 and centrifugation in an Eppendorf microcentrifuge. VLDL was separated from LDL and HDL by use of a Beckman TL 100 ultracentrifuge. The value for VLDL cholesterol was taken as the total cholesterol minus the cholesterol in the bottom fraction containing LDL plus HDL. VLDL cholesterol obtained in this way was always checked against the measured cholesterol in the top (VLDL-containing) fraction and verified to yield virtually identical results. Cholesterol and triglycerides in total plasma and subtractions were measured with a Baker Encore II automated analyzer. Our laboratory participates in the cholesterol standardization program of the Centers for Disease Control in Atlanta, Ga.
Apo E phenotyping was performed by isoelectric focusing on polyacrylamide gels after delipidation of the plasma VLDL fraction, as described by Warnick et al. 17 Furthermore, in most of the members of K625 the presence or absence of the common form of the E2 allele was determined by enzymatic amplification of patient DNA and subsequent allele-specific oligonucleotide hybridization (dot blotting). 118 These studies showed that the apo E2 phenotype detected by gel electrophoresis in K625 was, in every case, due to the common (arginine, 58 -»cysteine) E2 variant. Persons with the apo E 2-2 phenotype were excluded from the two-way analysis of variance and other analyses unless otherwise specified because homozygosity for the E2 allele is a well-known potent determinant of type III hyperlipidemia.
Estimation of /3-Very Low Density Lipoprotein Cholesterol
The cholesterol to triglyceride ratio in /3-VLDL (average of intestinal and hepatic sources) is 0.59. 3 This compares with a cholesterol to triglyceride ratio of 0.21 in normal (pre-/3) VLDL. 3 In normal plasma the VLDL cholesterol to plasma triglyceride ratio is 0.17. This value was observed among non-FH persons with no E2 allele in the current study population and in a large population sample after exclusion of pregnant women or persons whose plasma contained chylomicrons or floating /J-lipoproteins. 19 Triglyceride in plasma (total TG) was assumed to be derived from /J-VLDL and normal VLDL having the previously discussed composition plus other triglycerides (OT). These assumptions lead to the following two equations:
where f is the fraction of measured VLDL cholesterol (VLDL-C) that is derived from /3-VLDL. The second equation assumes that f=0 for the normal population and provides a means to estimate OT. Assuming that other lipoprotein compositions are not markedly changed due to the presence of /3-VLDL, substituting OT from the second equation into the first, and then solving for estimated /3-VLDL-C as f(VLDL-C) yields the following:
If the result of this calculation was less than zero (as would likely occur if chylomicrons were present), the value was set to zero. If the result was greater than VLDL cholesterol (when the ratio of VLDL cholesterol to plasma triglycerides exceeded 0.36), then the value was set equal to VLDL cholesterol. This estimate of /3-VLDL cholesterol provides a quantitative measure that is useful for statistical analyses, and unlike the ratio of VLDL cholesterol to plasma triglycerides, does not require plasma triglycerides to be greater than 150 mg/dl to be a valid index of /3-VLDL levels.
Statistical Analyses
The SAS statistical software package was used for data analysis (SAS Institute, Inc., Cary, N.C.). Logarithmic transformation of triglycerides was done to normalize the distribution. Statistical tests included Student's t test, x 2 > Fisher's exact test, simple regression, and the Wilcoxon rank-sum test. Two-way analysis of covariance was performed with the SAS general linear model program to correct for potential confounding variables in a formal evaluation of interaction between the presence of FH and the apo E2 allele.
Results
There were 89 FH heterozygotes and 110 non-FH subjects in four pedigrees in which high plasma LDL levels were genetically linked to the LDL receptor locus. Clinical characteristics and screening lipids are presented in Tables 1 and 2 . As expected, there were significantly more cases of coronary heart disease (CHD) in FH patients. Furthermore, CHD occurred at a much younger age in FH (mean age, 47; range, 26-59 years) compared with the two non-FH cases (aged 59 and 69 years). Diabetes mellitus, treated hypertension, and cigarette smoking were relatively rare in these families, with no differences between FH and non-FH subjects. Interestingly, body mass index (BMI; body weight in kilograms divided by height in meters squared) was significantly lower in FH compared with non-FH subjects. Age and gender composition were not different between FH and non-FH pedigree members. Neither tuberous nor palmar xanthomas were seen in any patients.
Most of the baseline screening lipids, as expected, were significantly different in FH versus non-FH subjects. Measured LDL cholesterol was just over twice as high in FH patients as in non-FH subjects. Some of the older FH patients were taking medication for their hyperlipidemia, although in most cases, lipids had not been normalized by their treatment. We have made no correction for medication effects in any of our analyses, and FH patients taking lipidlowering medications have been included in all analyses. Results in Tables 1 and 2 do not include four FH Probability values refer to differences between FH and non-FH subjects in each category (by Wilcoxon rank-sum test).
•Estimated as described in text.
patients with an apo E 2-2 phenotype. There were no non-FH persons with the apo E 2-2 phenotype. Apo E allele frequencies determined from electrophoretic phenotyping were 0.27, 0.59, and 0.13 for the E2, E3, and E4 alleles, respectively, in FH patients and 0.13, 0.66, and 0.21, respectively, in non-FH subjects. The apo E2 allele frequency is probably higher in this sample, especially among FH patients, due to the high frequency in K625. Figure 1 shows the frequency of DLPIII in persons with or without a single E2 allele among non-FH and FH pedigree members. DLPIII was defined as a screening VLDL cholesterol to plasma triglyceride ratio greater than 0.30 and with a plasma triglyceride level greater than or equal to 150 mg/dl. The chance of displaying the DLPIII phenotype was not significantly increased for non-FH persons carrying the E2 allele. In contrast, the relative odds of expressing the DLPIII pattern were 13.6, comparing FH patients to those without a single E2 allele (p=0.003 by Fisher's exact test). Also shown in Figure 1 are analogous results with a cutoff value of 40 mg/dl for estimated /3-VLDL cholesterol (well above the 99th percentile in the non-FH group). Use of this more sensitive index of /3-VLDL produced identical results in the non-FH subjects, while the relative odds in FH subjects were 3.6 (/?=0.03 by Fisher's exact test). These results provide strong evidence for an interaction between FH and the apo E2 allele, resulting in increased /3-VLDL cholesterol levels.
Comparison of FH and non-FH subjects from the four pedigrees (see Table 2 ) showed a marked increase in the ratio of the VLDL cholesterol to plasma triglyceride ratio and a fivefold increase in mean estimated /3-VLDL among FH subjects (for both, /?<0.0001). Increases of these two indexes of /3-VLDL were not randomly distributed in FH patients. When examined by apo E phenotype as shown in Tables 3 and 4 , FH patients with a single E2 allele (apo E 3-2 and apo E 4-2 phenotypes) had consistently higher VLDL cholesterol to plasma triglyceride ratios (mean of 0. 26 allele (apo E 3-3, 4-3, and 4-4 phenotypes). In four FH patients with apo E 2-2 the mean VLDL cholesterol to plasma triglyceride ratio was 0.35, and estimated /3-VLDL was markedly elevated (mean, 111.7 mg/dl). Also of note in Tables 3 and 4 is the apparent lack of effect of the apo E locus among non-FH subjects. Furthermore, VLDL cholesterol to plasma triglyceride ratios and estimated /3-VLDL cholesterol levels were consistently higher in FH patients compared with non-FH subjects within each apo E phenotype category. Table 5 shows ages, BMIs, and lipid levels in FH patients with DLPIII compared with FH patients without DLPIII. Importantly, the DLPIII FH patients are more hyperlipidemic than their FH counterparts without DLPIII, having higher plasma total cholesterol, triglycerides, and VLDL cholesterol as well as increased estimated 0-VLDL cholesterol.
To formally evaluate interactions between FH and the apo E locus suggested in Tables 3 and 4 , a series of two-way analyses of covariance with correction for potential confounding variables were performed. Predictive variables examined included age, sex, BMI, presence of FH, presence of a single E2 allele (all with apo E 2-2 phenotype were excluded), and the two-way classification or interaction of FH with E2. Analyses were performed with either the VLDL cholesterol to plasma triglyceride ratio or the estimated /3-VLDL cholesterol level as the dependent variable. Gender had no independent effect in any analysis and was excluded from the final analysis of Age demonstrated strong, positive, simple univariate correlations with both the VLDL cholesterol to plasma triglyceride ratio and estimated /3-VLDL cholesterol, but the effects of age were different in FH versus non-FH groups ( Figure 2) . As a result, the interaction term of FH with age was statistically significant, justifying separate correction for age effects within the two FH groups (a nested model). For all ages (without BMI) with the VLDL cholesterol to plasma triglyceride ratio as the dependent variable, the final terms were age (nested within FH groups), presence of FH, presence of the E2 allele, and the interaction term FHx£2. All these covariates were statistically significant (p values of 0.0001, 0.032, 0.026, and 0.038, respectively). The overall model was highly predictive, with R 2 =0.3l and F=\l.l. For estimated /3-VLDL cholesterol, the same model was also highly predictive (i? 2 =0.36, F=21.6). The probability value for the interaction term where estimated /3-VLDL cholesterol was the dependent variable was 0.017.
The least-square-means estimates of the four cells from these analyses are shown in Figure 3 . The interaction is illustrated by the marked increases in VLDL cholesterol to plasma triglyceride ratio and estimated /3-VLDL cholesterol in the FH-with-£2 group compared with the FH-without-£2 group, while no effect for E2 was seen in the non-FH groups.
In analyses including BMI, 104 of 118 individuals over age 18 had weight and height measurements available. Among these, BMI made no additional contribution to age in models with the VLDL cholesterol to plasma triglyceride ratio as the dependent variable. Use of estimated /3-VLDL cholesterol as Figure 3 (with corresponding means ±SEM being 6.3 ±3.8, 6.9 ±7.5, 23.5+5.1, and 51.0±5.4).
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While the ratio of VLDL cholesterol to plasma triglyceride was normally distributed within the FH and non-FH groups, estimated /3-VLDL cholesterol levels were exponentially distributed due to many low and zero values. A low frequency of measurable 0-VLDL cholesterol levels is to be expected. Nevertheless, the striking results from analysis of covariance for estimated /3-VLDL cholesterol levels must be interpreted with caution because this analysis assumes a normally distributed variable.
No significant interactions were observed between FH and E2 for plasma total or measured LDL cholesterol, plasma triglycerides, HDL cholesterol, or measured VLDL cholesterol. In addition, no association or interaction with the apo E4 allele was seen for VLDL cholesterol to plasma triglyceride ratio or for estimated /3-VLDL.
Discussion
We have confirmed a significant interaction between the combined presence of a defect in the LDL receptor and the E2 allele, which results in a marked increase in the VLDL cholesterol to plasma triglyceride ratio, estimated /3-VLDL cholesterol levels, and prevalence of DLPIII. Estimated /J-VLDL cholesterol (age adjusted) was approximately 5 mg/dl in non-FH regardless of the presence or absence of an E2 allele. In contrast, in FH subjects without an E2 allele the estimated /3-VLDL cholesterol level was 17 mg/dl (23.5 mg/dl in adults over age 18 adjusted for age and BMI), while for FH subjects with an E2 present the level was 33 mg/dl (51.0 mg/dl in adults). The strong association between estimated /3-VLDL cholesterol and age within the FH-with-£2 group and the moderate correlations with BMI in adults suggests that the interaction between FH and E2 is at least partly age and BMI dependent.
The high prevalence (26%) of DLPIII among 43 FH patients with a single E2 allele is in striking contrast to the low prevalence of DLPIII in non-FH persons with one E2 allele (3%). In the FH subgroup with E2, an even higher percentage (30%) had estimated /3-VLDL cholesterol levels well above the 99th percentile of the non-FH group. The low prevalence of DLPIII in the non-FH group is consistent with a maximum 1.4% prevalence of DLPIII and possible DLPIII (with possible DLPIII included in the "other" category) in the general population over age 19 from the North American Lipid Research Clinics Program Prevalence Study. 20 The definition of definite DLPIII in that study included the presence of a /3 band in the d< 1.006 g/ml (VLDL) fraction on gel electrophoresis plus a ratio of VLDL cholesterol to plasma triglyceride greater than 0.30. In the absence of /3-VLDL detected by electrophoresis, a ratio greater than 0.30 was considered to indicate possible DLPIII. Thus, the combination of definite and possible DLPIII would be comparable to the definition of DLPIII used in our study.
In a family study by Uterman et al 21 the prevalence of DLPIII according to the definition used in our study could be calculated within apo E phenotypes from data presented in the "Appendix." Only one of 85 persons with a single E2 and two of 72 persons with no E2 allele had DLPIII (VLDL cholesterol to plasma triglyceride ratio >0.30, with triglycerides >150 mg/ dl). This compares with 17 of 36 patients having DLPIII with the apo E 2-2 phenotype. Many of the apo E 2-2 subjects had been selected as probands having DLPIII (according to a definition based on electrophoretic pattern of lipoproteins). If the ratio of VLDL cholesterol to plasma triglycerides alone had been used as the criterion, a much larger percentage of the apo E 2-2 subjects and those with other apo E phenotypes would have been considered to have DLPIII. Indeed, Uterman et al 22 did report that a single copy of the E2 allele resulted in a VLDL cholesterol to plasma triglyceride ratio intermediate between that of E2 homozygotes and those without the allele. However, most of these additional persons with elevated VLDL cholesterol to plasma triglyceride ratios had plasma triglyceride levels below 150 mg/dl.
The interaction between FH and the E2 allele seen in this study was not likely due to any unusual rare apo E genes. In a separate study of 100 apo E2 alleles in our population, only two rare E2 genes were found. 18 In kindred K625, pedigree members were tested by allele-specific oligonucleotide hybridization for the presence of the common E2 and E3 alleles and by direct DNA sequencing to disclose any rare E2 or E3 alleles. Only the common alleles were present. 1 Furthermore, in the other pedigrees in this study a similar effect for the E2 allele was observed, and its gene frequency was similar to that reported in other population studies. It is unlikely that extremely rare alternative apo E2 or E3 alleles would account for such consistent observations in these four large and genetically diverse FH pedigrees.
The method we have used to estimate /3-VLDL cholesterol levels in this population is indirect. There are no direct confirmations of the validity of our estimate of /3-VLDL cholesterol levels with the use of comparisons of isolated /3-VLDL in large groups. However, in plasma from all seven FH DLPIII patients from kindred K625 we observed a broad /3 pattern and /3 migration of isolated VLDL. All seven had estimated /3-VLDL cholesterol levels above 40 mg/dl (mean±SD, 83.1±37.7 mg/dl)-clearly elevated compared with those of non-FH subjects and FH patients without the E2 allele. In addition, a single FH patient from this pedigree with apo E 3-3 had no detectable /3-VLDL on gel electrophoresis and had an estimated /3-VLDL cholesterol level of zero. Similar evaluations and the addition of standardized quantitative methods for /3-VLDL measurement would be helpful in more individuals to verify this method for estimation. The finding of a comparable interaction with the use of the VLDL cholesterol to plasma triglyceride ratio or estimated /3-VLDL cholesterol level provides additional support for the use of estimated /3-VLDL cholesterol in this study. The VLDL cholesterol to plasma triglyceride ratio is a reasonably good indicator of the presence of "floating-/?" lipoproteins or /3-VLDL. 7 Our estimate for /3-VLDL cholesterol is a straightforward extension of this concept. An obvious limitation of estimated /3-VLDL cholesterol as defined for this study is its dependence on assumptions of fixed particle compositions rather than direct measurements. In reality, /3-VLDLs are heterogeneous lipoproteins in the VLDL and intermediate density lipoprotein (IDL) density ranges and may possess a relatively wide range of cholesterol to triglyceride ratios. In this study the VLDL fraction was separated from LDL and HDL at plasma density (d=1.006 g/ml) and thus did not include IDL (d=1.006-1.019 g/ml).
Finding elevated levels of /3-VLDL in FH is consistent with our current understanding of VLDL and remnant metabolism. Normal VLDL processing to LDL and/or VLDL remnant removal appears to require a normal interaction between apo E and the apo B,E (LDL) receptor. In normal subjects cyclohexanedione modification of VLDL apo B interferes with apo B binding to the apo B,E (LDL) receptor and results in a 50% reduction in the rate of conversion of VLDL-derived IDL into LDL. 23 Furthermore, at least some patients with FH may have increased net LDL apo B transport because of a decrease in VLDL (or IDL) removal by the liver before its conversion to LDL.
-
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- 26 In a kinetic study of different VLDL subfractions in homozygous FH patients, James et al 27 found fourfold increases in IDLs and less marked increases in small VLDL, while concentrations of larger VLDL were unaltered compared with those of controls. Furthermore, the smaller VLDLs in FH homozygotes were enriched with cholesterol and depleted in triglycerides. These differences in concentration and composition were accompanied by increased conversion of large VLDL to small VLDL and a defect in remnant processing. Consistent with these observations was the finding in a subset of Watanabe heritable hyperlipidemic rabbits of increased levels of VLDL with properties similar to those of /3-VLDL (including increased deposition into macrophages), which was correlated with increased coronary atherosclerosis severity. 28 The impairment of VLDL remnant removal in FH should be exaggerated by any further derangement of the interaction between apo E and the apo B,E (LDL) receptor. Binding studies have clearly demonstrated markedly reduced binding between this receptor and isolated apo E-2 compared with apo E-3. 3 Thus, the combined presence of heterozygous FH and an apo E 2-2 phenotype should result in an exaggeration of the delayed clearance or conversion of VLDL found in either condition alone. A patient with heterozygous FH and apo E 2-2 who displayed a clear DLPIII phenotype as well as elevated plasma LDL was previously reported. 4 A single patient with FH and an apo E 4-2 phenotype having a DLPIII pattern has also been reported. 5 The investigators of the former study suggested that FH may be one stimulus, which, together with apo E 2-2, leads to DLPIII. The very high estimated /3-VLDL cholesterol levels found in four FH patients with apo E 2-2 in our study provide further evidence for this suggestion. Other factors increasing the risk of DLPIII in persons with apo E 2-2 are obesity and older age, probably because of increased lipoprotein synthesis. 2930 Significant correlations of estimated /3-VLDL cholesterol with age and BMI in our study are therefore consistent with expectations.
Our finding of a relatively common occurrence of DLPIII among FH patients with a single E2 allele illustrates the precarious metabolic status of VLDL in FH. Estimated /3-VLDL cholesterol was already increased in FH subjects, but addition of a single E2 allele doubled the concentration in adults. No such effect was seen in the non-FH group. Total plasma cholesterol, triglycerides, and VLDL cholesterol were also elevated in the DLPIII FH patients compared with other FH patients. Patients with DLPIII in this study had lipid levels (other than LDL cholesterol) that were largely within the range of type III hyperlipoproteinemia reported by Morganroth et al, 31 although the average elevation in triglycerides was somewhat less striking. If /3-VLDLs are indeed highly atherogenic lipoproteins, then persons with FH having elevated /3-VLDL levels would be expected to be at higher risk for early coronary disease than FH subjects without /3-VLDL. Observations in the Watanabe heritable hyperlipidemic rabbit model for homozygous FH would seem to corroborate this hypothesis. 28 The striking occurrence of coronary disease before age 55 in each of five sisters with FH (pedigree K625), all of whom also had an apo E 3-2 phenotype, indeed suggests an increased risk. This hypothesis should be tested in a larger population sample of FH families.
Interestingly, two of the proband sisters in K625 were being treated with lipid-lowering drugs and did not have the DLPIII phenotype, even though untreated offspring who had both an LDL receptor defect and an E2 allele did have DLPIII. 1 These observations are consistent with the remarkable responsiveness of DLPIII to drug therapy, typically niacin, gemfibrozil, or clofibrate. 3 Recent studies with hydroxymethylglutaryl coenzyme A reductase inhibitors also show marked improvement of lipids in DLPIII patients. 32 Treatment of FH patients with lipid-lowering regimens may thus reduce coronary disease risk not only by a decrease in LDL cholesterol but also by a potentially important reduction of plasma /3-VLDL cholesterol.
